BR112023002056A2 - Forma de dosagem oral sólida, e, método para preparar uma forma de dosagem oral sólida - Google Patents

Forma de dosagem oral sólida, e, método para preparar uma forma de dosagem oral sólida

Info

Publication number
BR112023002056A2
BR112023002056A2 BR112023002056A BR112023002056A BR112023002056A2 BR 112023002056 A2 BR112023002056 A2 BR 112023002056A2 BR 112023002056 A BR112023002056 A BR 112023002056A BR 112023002056 A BR112023002056 A BR 112023002056A BR 112023002056 A2 BR112023002056 A2 BR 112023002056A2
Authority
BR
Brazil
Prior art keywords
solid oral
dosage form
oral dosage
preparing
preparation
Prior art date
Application number
BR112023002056A
Other languages
English (en)
Inventor
Hye Lee Ji
Young Choi So
Jin Kim Sang
Hee Yang Yun
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of BR112023002056A2 publication Critical patent/BR112023002056A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMA DE DOSAGEM ORAL SÓLIDA, E, MÉTODO PARA PREPARAR UMA FORMA DE DOSAGEM ORAL SÓLIDA. O presente pedido refere-se a uma preparação oral sólida e a um método de preparação para a mesma, a preparação compreendendo grânulos, que compreendem: como um ingrediente ativo, um composto carbamato da fórmula química 1, ou um sal farmaceuticamente aceitável, um solvato, isômero ou um hidrato do mesmo; um diluente e um aglutinante.
BR112023002056A 2020-08-06 2021-08-06 Forma de dosagem oral sólida, e, método para preparar uma forma de dosagem oral sólida BR112023002056A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200098589 2020-08-06
PCT/KR2021/010391 WO2022031099A1 (ko) 2020-08-06 2021-08-06 카바메이트 화합물을 포함하는 경구용 고형 제제 및 이의 제조방법

Publications (1)

Publication Number Publication Date
BR112023002056A2 true BR112023002056A2 (pt) 2023-03-07

Family

ID=80118273

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002056A BR112023002056A2 (pt) 2020-08-06 2021-08-06 Forma de dosagem oral sólida, e, método para preparar uma forma de dosagem oral sólida

Country Status (13)

Country Link
US (1) US20230338295A1 (pt)
EP (1) EP4193987A1 (pt)
JP (1) JP2023536341A (pt)
KR (1) KR20230048032A (pt)
CN (1) CN116322641A (pt)
AU (1) AU2021321092A1 (pt)
BR (1) BR112023002056A2 (pt)
CA (1) CA3187349A1 (pt)
CL (1) CL2023000308A1 (pt)
CO (1) CO2023001204A2 (pt)
IL (1) IL300221A (pt)
MX (1) MX2023001525A (pt)
WO (1) WO2022031099A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
JP4409630B2 (ja) * 2008-02-21 2010-02-03 田辺三菱製薬株式会社 経口投与用固形製剤
MY155662A (en) 2009-06-22 2015-11-13 Sk Biopharmaceuticals Co Ltd Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
KR102293907B1 (ko) * 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
US20210346348A1 (en) * 2018-09-21 2021-11-11 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
CA3116195A1 (en) * 2018-10-19 2020-04-23 Sk Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing, alleviating or treating diabetic peripheral neuropathy or chemotherapy-induced peripheral neuropathy

Also Published As

Publication number Publication date
JP2023536341A (ja) 2023-08-24
CA3187349A1 (en) 2022-02-10
AU2021321092A1 (en) 2023-03-09
CL2023000308A1 (es) 2023-10-06
EP4193987A1 (en) 2023-06-14
CO2023001204A2 (es) 2023-04-17
MX2023001525A (es) 2023-03-06
IL300221A (en) 2023-03-01
KR20230048032A (ko) 2023-04-10
US20230338295A1 (en) 2023-10-26
CN116322641A (zh) 2023-06-23
WO2022031099A1 (ko) 2022-02-10

Similar Documents

Publication Publication Date Title
BR112023001195A2 (pt) Composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto pró-fármaco do mesmo, composto, método de preparação para composto ou racemato, estereoisômero, tautômero, composto isotopicamente rotulado, solvato, polimorfo, sal farmaceuticamente aceitável ou composto de pró-fármaco, composição farmacêutica, método para tratar uma doença associada com a ativação do caminho alternativo de complemento, e, uso do composto
MX2021012756A (es) Derivado de un anillo inhibidor de btk, metodo de preparacion de este y aplicacion farmaceutica para este.
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
BR112022010254A2 (pt) Composto heterocíclico contendo oxigênio representado pela fórmula i, método para preparar o composto heterocíclico contendo oxigênio, composto, composição farmacêutica e uso composto heterocíclico contendo oxigênio
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
BR112013017302A2 (pt) formulações de imunossupressor
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
MX2020003993A (es) Derivados de bencimidazol y sus usos.
BR112022010377A2 (pt) Novos tiromiméticos
BR112022001568A2 (pt) Composto, método para preparação do composto, composição farmacêutica, e, uso do composto
MX2021012105A (es) Compuestos de pirrol.
BR112021011325A2 (pt) Derivados de rapamicina
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
BR112022002107A2 (pt) Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
BR112021022255A2 (pt) Composto usado como inibidor de quinase e aplicação do mesmo
MX2021009971A (es) Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos.
BRPI0417844A (pt) derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina
MX2019014321A (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias.
MX2022008487A (es) Degradadores de smarca2-vhl.
BR112023002056A2 (pt) Forma de dosagem oral sólida, e, método para preparar uma forma de dosagem oral sólida
MX2022011242A (es) Inmunomodulación de o-het/aril azálidos.
MX2021014544A (es) Derivados de aminoglucosidos antibacterianos.
MX2021014458A (es) Compuestos triciclicos.